Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer

Trial Details

NCT ID

NCT07643012

Phase

NA

Sponsor

Rutgers, The State University of New Jersey

Status

RECRUITING

Cancer Type

Uterine Cancer

Interventions

• MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)

Locations (sample)

• New Brunswick, New Jersey, United States|40.48622,-74.45182

Key Eligibility Criteria

• Histologically confirmed endometrial carcinoma (endometrioid, serous, clear cell, carcinosarcoma, or dedifferentiated histology).
• Indication for adjuvant pelvic radiotherapy (± vaginal brachytherapy) for HIR defined by the ASTRO guidelines and GOG-99(7, 9) :
• High-grade histology (grade 2-3)
• Depth of myometrial invasion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.